All sponsors

ADARx Pharmaceuticals, Inc.

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-32
RECRUITING6
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO100%

Delay Index: of 5 active trials registered more than a year ago, 5 have moved their primary completion (readout) date by more than 6 months since first registration (median +29.9 months). See all sponsors →

Open ADARx Pharmaceuticals, Inc. on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
STOP-HAE
NCT06960213
P3RecruitingHereditary Angioedema; HAE902027-11-30 (+11 mo)
ADX-324
NCT05691361
P1/2Active, not recruitingHereditary Angioedema532027-12-31 (+48 mo)
PNH
NCT05876312
P1/2RecruitingParoxysmal Nocturnal Hemoglobinuria (PNH)502028-03-31 (+40 mo)
ADX-038
NCT07522099
P2RecruitingImmunoglobulin A Nephropathy (IgAN); Complement 3 Glomerulopathy (C3G)302028-07-10
ADX-038 Dose Level 2
NCT06989359
P2RecruitingIgAN; C3G452028-12-31 (+18 mo)
ADX-038
NCT06990269
P2RecruitingGeographic Atrophy Secondary to Age-related Macular Degeneration2402030-02-28 (+30 mo)
ADX-324 Dose Level 1
NCT07428499
P3RecruitingHereditary Angioedema (HAE); Hereditary Angioedema - Type 1902030-06-30